TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04069793

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available device
Description: A commercially available and registered with the FDA prosthesis equipped with a powered single-degree of freedom wrist and powered hand.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non FDA registered device
Description: An experimental, non FDA registered prosthesis equipped with a multi function wrist and a powered hand.
Study: NCT02149836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezogabine
Description: Treatment Week 1: 100mg of Ezogabine by mouth three times per day (total daily dose = 300mg) Treatment Week 2: dose will be increased to 150 mg Ezogabine by mouth three times per day (total daily dose = 450mg).~Treatment Week 3: dose will be increased to 200mg of Ezogabine by mouth three times per day (total daily dose = 600mg).~Treatment Week 4: dose will be increased to 250mg of Ezogabine by mouth three times per day (total daily dose = 750mg).~Treatment Week 5: dose will be increased to 300mg of Ezogabine by mouth three times per (total daily dose = 900mg).~Participants will continue to take 900mg of Ezogabine per day and return weekly to the clinic for the remainder of the study.~Following this primary outcome visit, participants will be instructed to taper the study medication over the following 3 weeks based on FDA recommended guidelines as follows:~250 mg po TID daily x 1 week, then 200 mg po daily x 1 week, then 100 mg po daily x 1 week, then discontinue
Study: NCT01662700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Study: NCT00527215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: starting dose determined by calculating a subject's total dose in the month preceding enrollment. Administered QM for 25 weeks. Change made as necessary to maintain a hemoglobin concentration within the target range os 10.0 - 12.0 g.dL
Study: NCT00083070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study: NCT03632681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Insulin
Description: Intranasal insulin
Study: NCT02114645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg oral estradiol valerate
Description: estrofem is given twice a day
Study: NCT03632681

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Intranasal placebo manufactured to mimic smell of insulin
Study: NCT02061722

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Imaging with [18F]MNI-659
Description: The radioligands \[11C\]raclopride and \[18F\]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of \[11C\]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of \[18F\]MNI-659 will be 185 MBq/70 kg of body weight ± 10%.
Study: NCT04569474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transparent dressing
Description: Use of sterile transparente dressing
Study: NCT01429987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plecanatide
Description: Subjects receive experimental study drug for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plecanatide
Description: Subjects receive experimental study drug for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plecanatide
Description: Subjects receive experimental study drug for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive experimental study drug for 12 weeks.
Study: NCT01745393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic Quality Improvement + Behavioral Counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Quality Improvement + Attention Control
Study: NCT01301560

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Gamma knife surgery for asymptomatic oligo-metastasis to brain from NSCLC

Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: Observation
Description: No local treatment
Study: NCT01794494

Intervention type: PROCEDURE
Intervention: Bypass surgery
Description: Patients are treated with femoro-popliteal bypass

Intervention type: PROCEDURE
Intervention: Endovascular recanalization
Description: Patients are treated with PTA or subintimal angioplasty
Study: NCT03308084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Administration of 10mg Dexamethasone IV intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administration of 10mg Dexamethasone IV intraoperatively
Study: NCT02218814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block, Bupivacaine
Description: Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL (100 mg) of Bupivacaine is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.~Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml of PF Normal Saline is deposited adjacent to the femoral artery at the level of inguinal crease.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block, Bupivacaine
Description: Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml (100 mg) of Bupivacaine is deposited adjacent to the femoral artery at the level of inguinal crease.~Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL of PF Normal Saline is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.
Study: NCT02539082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regenseal
Description: Regenseal, collagen, injection in the defect area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: placebo, normal saline, injection in the defect area
Study: NCT04500314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration device
Description: 20 patients will receive vibration training on vibration platform (Power Plate International, Irvine, California, USA) at a frequency of 25-30 Hz and amplitude of 3-5mm, plus traditional physical therapy program 3 sessions per week for total period of 8 weeks. The total duration of the WBV training stimulus will 10 min in first week and progress gradually to 25 min in the 8th week with regular increase by 5 minutes after each 2 successive weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine physical therapy treatment
Description: The program consists of 60 minutes supervised and individualized stretching exercise to all involved muscles followed by strengthening for affected muscles, mobilizing exercise for the joints involved to increase the joint range of motion, in addition to scar management techniques including pressure garments, inserts, and physical agent modalities , to avoid scar or contracture formation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine physical therapy treatment
Description: The program consists of 60 minutes supervised and individualized stretching exercise to all involved muscles followed by strengthening for affected muscles, mobilizing exercise for the joints involved to increase the joint range of motion, in addition to scar management techniques including pressure garments, inserts, and physical agent modalities , to avoid scar or contracture formation
Study: NCT06534424

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood or mouthwash sample

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood or mouthwash sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Receive tailored counseling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in phone discussion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discussion
Description: Participate in phone discussion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genotyping
Description: Undergo genotyping

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular Risk Assessment
Description: Undergo enhanced risk assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02421367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
Description: Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
Description: Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
Description: Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)
Study: NCT02198287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIX 1 XX inhalation solution
Description: single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01594632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jadelle
Description: LNG containing subdermal contraceptive implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sino-implant (II)
Description: LNG containing subdermal contraceptive implant
Study: NCT03697928

Intervention type: OTHER
Intervention: Exercise metabolism
Description: Participants will perform a series of exercises inside and outside the MRS/MRI scanner.
Study: NCT02411201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOTAREM
Description: Single intravenous injection of 0.1 mmol/kg body weight
Study: NCT04402268

Intervention type: DEVICE
Intervention: Cardioverter-defibrillator
Description: We analyzed how many HCM patients reached an end-point of sudden cardiac death defined as adequate intervention of cardioverter-defibrillator or sudden cardiac arrest.

Intervention type: DEVICE
Intervention: Cardioverter-defibrillator
Description: We analyzed how many HCM patients reached an end-point of sudden cardiac death defined as adequate intervention of cardioverter-defibrillator or sudden cardiac arrest.

Intervention type: DEVICE
Intervention: Cardioverter-defibrillator
Description: We analyzed how many HCM patients reached an end-point of sudden cardiac death defined as adequate intervention of cardioverter-defibrillator or sudden cardiac arrest.
Study: NCT03986346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed dye laser
Description: The scar will receive PDL 585 nm using a 7 mm spot size. First treatment will be within 1 year post injury.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized care
Description: the scar will receive standardized care such as scar massage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized care
Description: the scar will receive standardized care such as scar massage.
Study: NCT04611685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: Immediately after the operation, the patient is given (parecoxib 40 mg + sodium chloride 100 ml) intravenously once, and then given (loxoprofen 60 mg) orally twice a day during the first three postoperative days.
Study: NCT02765672

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitness-to-Drive Screening Measure (FTDS)
Description: Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness-to-Drive Screening Measure (FTDS)
Description: Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simulated Driving Evaluation
Description: This involves driving a simulator fitted simulated drives engineered to to address Veteran's driving concerns such as reactions to other drivers and road conditions(e.g. debris). The simulator is used at baseline and at post-test1 and 2. The intervention and traffic safety education session 3 also occurs using the driving simulator.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulated Driving Evaluation
Description: This involves driving a simulator fitted simulated drives engineered to to address Veteran's driving concerns such as reactions to other drivers and road conditions(e.g. debris). The simulator is used at baseline and at post-test1 and 2. The intervention and traffic safety education session 3 also occurs using the driving simulator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Driving Safety Education
Description: This involves the following: Session1: general traffic safety discussion; Session 2: Rules of the road and acknowledgement of the road discussion and Session 3: driving the simulator without any feedback from traffic safety professional

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Driving Intervention (OT-DI)
Description: This has three sessions: 1. Driving evaluator reviews explicit driving errors with Combat Veteran; 2. driving evaluator provide tailored strategies to mitigate errors; Combat Veteran drives simulator with targeted feedback from driving evaluator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: On-road driving test
Description: This involves and on-road driving test supervised by Driving Rehabilitation Specialist. To be completed at baseline and at month 5

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Driving triggers evaluation
Description: The simulator-drives evaluation group will evaluate the current simulator-triggers prior to baseline testing
Study: NCT03176784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 14 mg and 7 mg nicotine patches used. See arms for specific durations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 14 mg and 7 mg nicotine patches used. See arms for specific durations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.
Study: NCT04611685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Immediately after the operation, the patient is given (tramadol 100 mg) intramuscularly once, and then given (tramcontin 100 mg) orally twice a day during the first three postoperative days.
Study: NCT01735747

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: WBRT was given five times a week at 2 gray (Gy)/d until the whole brain radiotherapy dose reached 40 gray. The patients were given concurrent temozolomide (75mg/m2, orally) daily during radiotherapy until the end of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nedaplatin
Description: nedaplatin (80mg/m2 i.v., day 1), 28 day schedule, performed four weeks after radiotherapy.A maximum of six cycles were applied.
Study: NCT03176784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.
Study: NCT01735747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: vincristine (1.4mg/m2 i.v., day 1)28 day schedule,performed four weeks after radiotherapy.A maximum of six cycles were applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (200mg/m2 orally, days 1-5, Each cycle was 4 weeks ), performed four weeks after radiotherapy. A maximum of six cycles were applied.
Study: NCT01045772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilonacept
Description: 160mg of rilonacept 1x/week
Study: NCT04576637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurophysiological monitoring during intubation
Description: In the operating room patients will be connected to the anesthesia monitor and an IV line as standard clinical practice. Participants will receive oxygen and an IV infusion of 1-3 ng/ml remifentanil via TCI infusion pump to achieve mild sedation. Patients will then be connected to the neurophysiological electrodes to monitor for EEG, EMG, SSEP and MEP signals. After preparing the videolaryngoscope, anesthesia induction will be achieved with the use of IV ketamine 2mg/kg. Then the anesthesiologist will perform a clinical and ECG reading assessment to ensure that the patient is anesthetized and will be able to titrate more ketamine as needed to achieve hypnosis. A biteblock will be located to prevent teeth damage. A neurophysiological baseline recordings will then be performed by a neurophysiologist. The videolaryngoscope will then be inserted, during which a second neurophysiological testing will be performed to ensure the patients safety. Then mechanical ventilation will be initiated.
Study: NCT03129581

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Counseling
Description: Counseling to only eat during a restricted amount of time.
Study: NCT02114645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg oral estradiol valerate
Description: estrofem is given twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg oral estradiol valerate
Description: estrofem is given twice a day
Study: NCT03176784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Pill
Description: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Pill
Description: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
Study: NCT03492970

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hourly dosing of the nychtemeral secretion of melatonin
Description: Hourly dosing of the nychtemeral secretion of melatonin links and with sleep disorders and behavior of adult patients with SMS
Study: NCT01087021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Study: NCT03655275

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP prolotherapy
Description: PRP prolotherapy By injection 2.5ml of PRP at an interval of 2 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Saline prolotherapy
Description: Saline prolotherapy Injection 2.5 ml of saline at an interval of 2 weeks.
Study: NCT03028896

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 90° rotational technique
Description: the LMA FlexibleTM was rotated counter-clockwise through 90°
Study: NCT02154724

Intervention type: DEVICE
Group type: OTHER
Intervention: aDBS
Description: The aDBS is applied for 2 hours for two days with two different modalities (aDBS and DBS) in random order.

Intervention type: DEVICE
Group type: OTHER
Intervention: DBS
Description: The aDBS s applied for two hous in DBS modality.
Study: NCT02114645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg oral estradiol valerate
Description: estrofem is given twice a day
Study: NCT03950856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5. mL dose.
Study: NCT01983111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: Dosage and administration: This one patch should be attached every 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol/acetaminophen
Description: Amount of drug ingredients~: Acetaminophen 325 mg and Tramadol hydrochloride 37.5 mg in 1 tablet of this drug.~Dosage and administration:~Adjust dose depending on a patient's pain severity and treatment response. Starting at the initial dose of 2 tablets, usually administer 4 tablets per dose, twice daily. At a dosing interval of at least 12 hr, the daily dose should not exceed 8 tablets.